GSK recalls two lots of migraine medication: IMITREX Injection

GlaxoSmithKline Inc., in consultation with Health Canada, is voluntarily recalling two lots of “IMITREX Injection”, a migraine medication packaged in pre-filled syringes with an accompanying sterile needle for injection. The needles come with plastic shields that are designed to keep them free of contamination. Needles in the affected lots may be protruding through the needle shield. The protruding needle is no longer sterile and as such, there is a potential risk of infection to consumers when using the product.

Patients who have IMITREX injection from the affected lots should not use the product, and should return it to their pharmacist. If you have used IMITREX injection in the past three months, contact your healthcare professional. Report any adverse events using this product to Health Canada . Contact GSK Inc. at 1-800-387-7374 for more information about returning the product.